March 29, 2020
Mycosis Fungoides

Mycosis Fungoides Market outlook 2019 shows growth drivers, opportunities and forecast analysis to 2027

The global market for Mycosis Fungoides is anticipated to expand at CAGR by 4.9 per cent from 2019 to 2027.

Mycosis Fungoides is most commonly seen in primary cutaneous lymphoma. Progression of the disease is slow and indolent, with a challenging diagnosis at the early stage of the disease requiring accurate clinical-histopathological correlation. It is a rare disease which usually occurs in adults over 50 years of age, the ratio of its occurrence in men to women is 2:1.

According to the research cited by the National Institute of Health (NIH), the global prevalence rate of Mycosis Fungoides is between 1 per 100,000 and 350,000 individuals. Approximately 70% of patients with cutaneous T cell lymphoma are seen. There’s no permanent cure for the disease. The treatment regimen is decided by the oncologist as to the manifestation of clinical symptoms during the course of the disease.

Access Free Sample Copy of Research Report:

[Note: Our Free Complimentary Sample Report Accommodate a Brief Introduction To The Synopsis, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology are also Included]

For the treatment, either individual or combination therapy is considered. In stage 1 a combination of topical steroid therapy, mechlorethamine gel and localized radiation therapy is recommended by physicians worldwide. Stage 2 HDAC inhibitors and extracorporeal photopheresis have been approved for the treatment of Mycosis Fungoides. In the late stage of the disease, monoclonal antibodies are administered by systemic circulation in order to reduce the spread of the disease to internal organs. Poteligeo (mogamulizumab) has recently been approved by USFDA, which will further increase the demand for monoclonal antibodies as a first-line treatment for Mycosis Fungoides.

For Any Query, Ask Our Expert at

In the regional segment of North America, the market represents a market share of 31.8%. The major contributing factors favouring its excellent market growth are rising incidence of Mycosis Fungoides and stringent treatment guidelines stipulated by USFDA. The home of key players such as Astellas Pharma, Sanofi S.A., Soligenix, Inc., Yaupon Therapeutics, etc. is further boosting the market growth in the North American region. With a market share of 28.4%, Europe is in second place due to the strategic collaboration between academic research institutes and biopharmaceutical giants in the development of novel drugs for the treatment of mycosis fungoides. Affordable reimbursement scenario further strengthens the growth of the European market. The Asia Pacific currently holds 16.2% of its population and will be the fastest-growing market due to the supportive regulatory environment provided by local health agencies and the proactive government initiative to treat orphan and rare diseases.

Astellas Pharma, Bayer AG, Dover Medical and Scientific Equipment, Ltd., Elorac, Inc., Kyowa Kirin, Inc., Macopharma, Sanofi SA, Soligenix, Inc., Varian Medical Systems and Yaupon Therapeutics are the leading biopharmaceutical giants in the market for Mycosis Fungoides.

Rising incidence of Mycosis Fungoides in patients over 50 years of age Affordable reimbursement scenario for medicines used in the treatment of Mycosis Fungoides in developed regions Significant increase in demand for monoclonal antibodies as a promising first-line therapy agent during the forecast period.

Key questions answered in this report

  • Who are the major biopharmaceutical companies actively engaged in the development of medicines for the treatment of mycosis fungoides?
  • What are the DRO’s related to the market growth assessed as per the latest market trend?
  • What is the disease pathology pertaining to mycosis fungoides and explain its different stages?
  • What is the individual and combinatorial therapy employed for the treatment of mycosis fungoides?
  • What is the prevalence rate of mycosis fungoides in developing regions such as Asia Pacific, MEA and LATAM?

Access Free Sample Copy of Research Report:

Leave a Reply

Your email address will not be published. Required fields are marked *